Neuropeptide Y and somatostatin inhibit stimulated cyclic AMP production in rabbit ciliary processes

References

• Waitzman M. B., Woods W. D. Some characteristics of an adenyl cyclase preparation from rabbit ciliary process tissue. Exp. Eye Res. 1971; 12: 99–111
   PubMedGoogle Scholar
• Sears M. L. Regulation of aqueous flow by the adenylate cyclase receptor complex in the ciliary epithelium. Am. J. Ophthalmol. 1985; 100: 194–198
   PubMed Web of Science ®Google Scholar
• Sears M. L., Caprioli J., Kondo K., Bausher L. A mechanism for the control of aqueous humor formation. Glaucoma: Applied Pharmacology in Medical Treatment, S. M. Drance, A. H. Neufeld. Grune & Stratton, Inc., Orlando, FL 1984; 303–324
   Google Scholar
• Gregory D., Sears M., Bausher L., Mishima H., Mead A. Intraocular pressure and aqueous flow are decreased by cholera toxin. Invest. Ophthalmol. Vis. Sci. 1981; 20: 371–381
   PubMed Web of Science ®Google Scholar
• Caprioli J., Sears M. Forskolin lowers intraocular pressure in rabbits, monkeys, and man. The Lancet 1983; 1: 958
   PubMed Web of Science ®Google Scholar
• Caprioli J., Sears M., Bausher L., Gregory D., Mead A. Forskolin lowers intraocular pressure by reducing aqueous flow. Invest. Ophthalmol. Vis. Sci. 1984; 25: 268–277
   PubMed Web of Science ®Google Scholar
• Burstein N. L., Sears M. L., Mead A. Aqueous flow in human eyes is reduced by forskolin, a potent adenylate cyclase activator. Exp. Eye Res. 1984; 39: 745–749
   PubMed Web of Science ®Google Scholar
• Neufeld A. H. The mechanism of action of adrenergic drugs in the eye. Glaucoma: Applied Pharmacology in Medical Treatment, S. M. Drance, A. H. Neufeld. Grune & Stratton, Inc., Orlando, FL 1984; 277–301
   Google Scholar
• Mittag T. W., Tormay A., Podos S. M. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes. J. Pharmacol. Exp. Therap. 1987; 241: 230–235
   PubMed Web of Science ®Google Scholar
• Bartels S. P., Lee S. R., Neufeld A. H. The effects of forskolin on cyclic AMP, intraocular pressure and aqueous humor formation in rabbits. Current Eye Res. 1987; 6: 307–320
   PubMed Web of Science ®Google Scholar
• Mittag T. W., Tormay A. Drug responses of adenylate cyclase in iris‐ciliary body determined by adenine labelling. Invest. Ophthalmol. Vis. Sci. 1985; 26: 396–399
   PubMed Web of Science ®Google Scholar
• Bausher L. P., Gregory D. S., Sears M. L. Interaction between alpha2 ‐ and beta2‐adrenergic receptors in rabbit ciliary processes. Current Eye Res. 1987; 6: 497–505
   PubMed Web of Science ®Google Scholar
• Bausher L. P., Gregory D. S., Sears M. L. Alpha2‐adrenergic and VIP receptors in rabbit ciliary processes interact. Current Eye Res. 1989; 8: 47–54
   PubMed Web of Science ®Google Scholar
• Jumblatt J. E., North G. T., Hackmiller R. C. Muscarinic cholinergic inhibition of adenylate cyclase in rabbit ciliary processes. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1988; 29: 324
   Google Scholar
• Butler J. M., Ruskell G. L., Cole D. F., Unger W. G., Zhang S. Q., Blank M. A., McGregor G. P., Bloom S. R. Effects of VIIth (facial) nerve degeneration on vaso‐active intestinal polypeptide and substance P levels in ocular and orbital tissues of the rabbit. Exp. Eye Res. 1984; 39: 523–532
   PubMed Web of Science ®Google Scholar
• Stone R. A. Vasoactive intestinal polypeptide and the ocular innervation. Invest. Ophthalmol. Vis. Sci. 1986; 27: 951–957
   PubMed Web of Science ®Google Scholar
• Nilsson S. F.E., Sperber G. O., Bill A. Effects of vasoactive intestinal polypeptide (VIP) on intraocular pressure, facility of outflow and formation of aqueous humor in the monkey. Exp. Eye Res. 1986; 43: 849–857
   PubMed Web of Science ®Google Scholar
• Hayashi K., Masuda K. Effects of vasoactive intestinal polypeptide (VIP) and cyclic AMP on the isolated sphincter pupillae muscles of the albino rabbit. Jpn. J. Ophthalmol. 1982; 26: 437–442
   PubMedGoogle Scholar
• Hayashi K., Mochizuki M., Masuda K. Effects of vasoactive intestinal polypeptide (VIP) and cyclic AMP on the isolated dilator pupillae muscle of the albino rabbit. Jpn. J. Ophthalmol. 1983; 27: 647–654
   PubMedGoogle Scholar
• Piccone M., Littzi J., Krupin T., Stone R. A., Davis M., Wax M. B. Effects of NPY on the isolated rabbit iris dilator muscle. Invest. Ophthalmol. Vis. Sci. 1988; 29: 330–332
   PubMedGoogle Scholar
• Ohia S. E., Jumblatt J. E. Effect of neuropeptide Y on norepinephrine release in the rabbit iris‐ciliary body. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1989; 30: 21
   Google Scholar
• Stone R. A. Neuropeptide Y and the innervation of the human eye. Exp. Eye Res. 1986; 42: 349–355
   PubMed Web of Science ®Google Scholar
• Stone R. A., Laties A. M., Emson P. C. Neuropeptide Y and the ocular innervation of the rat, guinea pig, cat and monkey. Neuroscience 1986; 17: 1207–1216
   PubMedGoogle Scholar
• Bruun A., Ehinger B., Sundler F., Tornqvist K., Uddman R. Neuropeptide Y immunoreactive neurons in the guinea‐pig uvea and retina. Invest. Ophthalmol. Vis. Sci. 1984; 25: 1113–1123
   PubMed Web of Science ®Google Scholar
• Allen J. M., McGregor G. P., Adrian T. E., Bloom S. R., Zhang S. Q., Ennis K. W., Unger W. G. Reduction of neuropeptide Y (NPY) in the rabbit iris‐ciliary body after chronic sympathectomy. Exp. Eye Res. 1983; 37: 213–215
   PubMed Web of Science ®Google Scholar
• Emson P. C., DeQuidt M. E. NPY ‐ a new member of the pancreatic polypeptide family. Trends in Neurosciences 1984; 7: 31–35
   Google Scholar
• Brecha N. Retinal neurotransmitters: histochemical and biochemical studies. Chemical Neuroanatomy, P. Emson. Raven Press, New York, NY 1983; 85–129
   Google Scholar
• Unger W. G., Butler J. M., Cole D. F., Bloom S. R., McGregor G. P. Substance P, vasoactive intestinal polypeptide (VIP) and somatostatin levels in ocular tissue of normal and sensorily denervated rabbit eyes. Exp. Eye Res. 1981; 32: 797–801
   PubMed Web of Science ®Google Scholar
• Brown D. R. Intracellular mediators of peptide action in the intestine and airways. Focus on ion transport function. Am. Rev. Respir. Dis. 1987; 136: s43–s48
   PubMedGoogle Scholar
• Saria A., Beubler E. Neuropeptide Y (NPY) and peptide YY (PYY) inhibit prostaglandin E2‐induced fluid and electrolyte secretion in the rat jejunum in vivo. Eur. J. Pharmacol. 1985; 119: 47–52
   PubMedGoogle Scholar
• Servin A. L., Rouyer‐Fessard C., Balasubramanian A., Saint Pierre S., Laburthe M. Peptide‐YY and neuropeptide‐Y inhibit vasoactive intestinal peptide‐stimulated adenosine 3',5'‐monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide‐YY‐preferring receptors. Endocrinology 1989; 124: 692–700
   PubMed Web of Science ®Google Scholar
• Ekblad E., Hakanson R., Sundler F. VIP coexists with NPY in intramural neurons of rat small intestine. Regul. Peptides 1984; 10: 47–55
   PubMedGoogle Scholar
• Kassis S., Olasmaa M., Terenius L., Fishman P. H. Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin‐sensitive G protein. J. Biol. Chem. 1987; 262: 3429–3431
   PubMed Web of Science ®Google Scholar
• Carter R. F., Bitar K. N., Zfass A. M., Makhlouf G. M. Inhibition of VIP‐stimulated intestinal secretion and cyclic AMP production by somatostatin in the rat. Gastroenterology 1978; 74: 726–730
   PubMedGoogle Scholar
• Guandalini S., Kachur J. F., Smith P. L., Miller R. J., Field M. In vitro effects of somatostatin on ion transport in rabbit intestine. Am. J. Physiol. 1980; 238: G67–G74
   PubMedGoogle Scholar
• Barber D. L., Gregor M., Soll A. H. Somatostatin and muscarinic inhibition of canine enteric endocrine cells: cellular mechanisms. Am. J. Physiol. 1987; 253: G684–G689
   Google Scholar
• Owyang C., Wiley J. Somatostatin inhibits intestinal motility via modulation of cyclic AMP‐dependent cholinergic transmission. Somatostatin: Basic and Clinical Status, S. Reichlin. Plenum Press, New York, NY 1987; 253–258
   Google Scholar
• Williams G., Anderson J. V., Bloom S. R. Treatment of gut‐associated neuroendocrine tumors with the long‐acting somatostatin analog, SMS 201–995. Somatostatin: Basic and Clinical Status, S. Reichlin. Plenum Press, New York, NY 1987; 343–356
   Google Scholar
• Petrenko S., Olianas M. C., Onali P., Gessa G. L. Neuropeptide Y inhibits forskolin‐stimulated adenylate cyclase activity in rat hippocampus. Eur. J. Pharmacol. 1987; 136: 425–428
   PubMedGoogle Scholar
• Gooch J. M., Hackmiller R. C., Jumblatt J. E. Neuropeptide Y modulates adenylate cyclase in the rabbit iris and ciliary epithelium. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1989; 30: 21
   Google Scholar
• Tran V. T., Beal M. F., Martin J. B. Two types of somatostatin receptors differentiated by cyclic somatostatin analogs. Science 1985; 228: 492–495
   PubMed Web of Science ®Google Scholar
• Bylund D. B., U'Prichard D. C. Characterization of alpha1‐ and alpha2‐adrenergic receptors. Int. Rev. Neurobiol. 1983; 24: 343–431
   PubMed Web of Science ®Google Scholar
• Coakes R. L., Brubaker R. F. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch. Ophthalmol. 1987; 96: 2045–2048
   Google Scholar
• Steidl S., Serle J., Wang R. ‐F., Podos S., Siddique A. Selective alpha adrenergic agents in cynomolgus monkeys. Invest. Ophthalmol. Vis. Sci. (Suppl.) 1988; 29: 15
   Google Scholar
• Lee D. A., Topper J. E., Brubaker R. F. Effect of clonidine on aqueous humor flow in normal human eyes. Exp. Eye Res. 1984; 38: 239–246
   PubMed Web of Science ®Google Scholar
• Gharagozloo N. Z., Relf S. J., Brubaker R. F. Aqueous flow is reduced by the alpha‐adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology 1988; 95: 1217–1220
   PubMed Web of Science ®Google Scholar